Suppr超能文献

女性对药物性出生缺陷风险咨询的看法。

Women's perspectives on counseling about risks for medication-induced birth defects.

作者信息

Santucci Aimee K, Gold Melanie A, Akers Aletha Y, Borrero Sonya, Schwarz Eleanor Bimla

机构信息

Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

出版信息

Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618.

Abstract

PURPOSE

This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs).

METHODS

We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus.

RESULTS

Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP.

CONCLUSIONS

Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.

摘要

目的

本定性研究探讨了女性在接受药物致畸性咨询方面的经历,以及她们希望如何以及何时从医疗保健提供者(HCPs)处获得有关药物致畸性的信息。

方法

我们在宾夕法尼亚州匹兹堡对36名育龄女性(18 - 45岁)进行了四个焦点小组访谈。21名女性正在使用药物治疗慢性健康状况,其中两名怀孕。由三名独立编码员采用扎根理论方法进行内容分析。通过共识解决分歧。

结果

女性报告称依赖医疗保健提供者获取有关药物对妊娠致畸风险的信息,但觉得所提供的信息并不总是全面的。女性希望医疗保健提供者在开药时就开始讨论潜在致畸药物,无论该女性是否有性行为或正在计划怀孕。女性希望获得关于胎儿所有潜在结局的清晰信息。女性报告称对有效的致畸风险咨询至关重要的因素包括隐私、有足够时间讨论该话题以及与医疗保健提供者的信任关系。

结论

育龄女性认为,通过在开药时常规讨论致畸风险,可以改善关于药物可能致畸作用的信息提供。

相似文献

2
Perspectives of primary care clinicians on teratogenic risk counseling.基层医疗临床医生对致畸风险咨询的看法。
Birth Defects Res A Clin Mol Teratol. 2009 Oct;85(10):858-63. doi: 10.1002/bdra.20599.

引用本文的文献

1
Special Considerations for Women of Reproductive Age on Anticoagulation.生育年龄妇女抗凝的特殊考虑。
J Gen Intern Med. 2022 Aug;37(11):2803-2810. doi: 10.1007/s11606-022-07528-y. Epub 2022 May 31.
6
Pharmacists and Contraception in the Inpatient Setting.住院环境中的药剂师与避孕
Pharmacy (Basel). 2020 May 9;8(2):82. doi: 10.3390/pharmacy8020082.

本文引用的文献

8
Three approaches to qualitative content analysis.定性内容分析的三种方法。
Qual Health Res. 2005 Nov;15(9):1277-88. doi: 10.1177/1049732305276687.
10
Prescription drug use in pregnancy.孕期处方药的使用。
Am J Obstet Gynecol. 2004 Aug;191(2):398-407. doi: 10.1016/j.ajog.2004.04.025.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验